Diseases of the Nervous System, Phase III

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this phase IIIb study is to assess the long-term safety, tolerability, and immunogenicity of the subcutaneous (SC) treatment with Immune Globulin Subcutaneous (IGSC) facilitated with recombinant human hyaluronidase (rHuPH20) (HYQVIA/HyQvia) in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who have completed Baxalta Clinical Study Protocol 161403 Epoch 1 without CIDP worsening.

Trial with
Baxalta US Inc.
Ages
18 years and older
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Joan Nye

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Bhaskar Roy, MBBS, MHS
Associate Professor of Neurology; Director of the Muscular Dystrophy Association adult care clinic, Neurology; Medical Director of the Electrodiagnostic Laboratory, Yale Medicine; Co-Chair of the IBM scientific interest group from IMACS, IMACS

Sub-Investigators

Last Updated
08/10/2023
Study HIC
#2000032120